drugset / Trial / NCT06781385
Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke
Phase 2
Enrolling by invitation
40 enrolled
Wake Forest University Health Sciences
Genentech, Inc. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine the safety and feasibility of using intra-arterial Tenecteplase in patients undergoing blood clot extraction for treatment of acute ischemic (non-bleeding) stroke. Intravenous Tenecteplase is FDA-approved to treat patients with an ischemic stroke presenting within the 0-3-hour time window.
Timeline
- Start
- 2025-09-22
- Primary completion
- 2026-09
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenecteplase | Protein / enzyme biologic | 0.125 mg/kg | Other |